AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Core Viewpoint - Aquestive Therapeutics, Inc. experienced a significant stock decline of approximately 40% following the FDA's identification of deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability ahead of the upcoming PDUFA action date [5]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with severe allergic reactions [5]. - The company is publicly traded on NASDAQ under the ticker symbol AQST [5]. Group 2: FDA Findings - The FDA identified deficiencies in the New Drug Application (NDA) for Anaphylm, which is an experimental sublingual film intended for treating severe allergic reactions, including anaphylaxis [5]. - These deficiencies currently prevent discussions regarding labeling and post-marketing requirements, which raises concerns about the application's likelihood of approval [5]. Group 3: Market Reaction - Following the FDA's announcement, shares of Aquestive Therapeutics plunged approximately 40% intraday, indicating a strong negative market reaction to the news [5].